Arvinas presents data at ASH 2025 showing enhanced antitumor activity with ARV-393 and glofitamab in DLBCL, initiation of combination cohort in 2026.
Data analysis has led to the decision to introduce a combined cohort in the Phase 1 clinical trial. In this trial, ARV-393 will be paired with glofitamab to explore a chemotherapy-free methodology for treating diffuse large B-cell lymphoma (DLBCL). The combined cohort is set to commence in the year 2026.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments